141 related articles for article (PubMed ID: 820673)
1. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
[TBL] [Abstract][Full Text] [Related]
2. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
[No Abstract] [Full Text] [Related]
3. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
Mathé G; Halle-Pannenko O; Bourut C
Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
[No Abstract] [Full Text] [Related]
4. Induction of macrophage antitumor activity by a mycobacterial fraction. In vivo and in vitro studies.
Rashid G; Gittel H; Ben-Efraim S
Anticancer Res; 1994; 14(3A):1083-7. PubMed ID: 8074454
[TBL] [Abstract][Full Text] [Related]
5. Biologically active components from mycobacterial cell walls. III. Production of experimental allergic encephalomyelitis in guinea-pigs.
Meyer TJ; Azuma I; Ribi EE
Immunology; 1975 Feb; 28(2):219-29. PubMed ID: 804436
[TBL] [Abstract][Full Text] [Related]
6. The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.
Mathe G; Halle-Pannenko O; Florentin I; Bruley-Rosset M; Kamel M; Hiu IJ; Bourut C
Eur J Cancer (1965); 1975 Nov; 11(11):801-7. PubMed ID: 767112
[No Abstract] [Full Text] [Related]
7. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
8. The methanol extract residue (MER) of bacillus calmette-guerin in cancer immunotherapy.
Domenick NP
Nurs Clin North Am; 1978 Jun; 13(2):369-80. PubMed ID: 353752
[No Abstract] [Full Text] [Related]
9. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
[No Abstract] [Full Text] [Related]
10. Effect of treatment with the methanol extraction residue fraction of killed tubercle bacilli (MER) on the development of spontaneous pulmonary metastases from syngeneic implants of tumor 3LL in C57B1 mice.
Treves AJ; Cohen IR; Feldman M; Weiss DW
Isr J Med Sci; 1976; 12(4-5):384-7. PubMed ID: 820672
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
Mathé G; Florentin I; Olsson L; Bruley-Rosset M; Schulz J; Kiger N; Orbach-Arbouys S; Schwarzenberg L; Pouillart P; de Vassal F
Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
[TBL] [Abstract][Full Text] [Related]
12. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
Moertel CG; Ritts RE; Schutt AJ; Hahn RG
Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
[TBL] [Abstract][Full Text] [Related]
13. Effects of methanol extraction residue of Bacillus calmette-Guérin in humans.
Perloff M; Holland JF; Lumb GJ; Bekesi JG
Cancer Res; 1977 Apr; 37(4):1191-6. PubMed ID: 321117
[TBL] [Abstract][Full Text] [Related]
14. [The protective activity of mycobacterial antigens. 3. Protective activity of killed mycobacterial bodies].
Stavri D; Anagnoste V; Drăghici D
Arch Roum Pathol Exp Microbiol; 1970; 29(1):91-101. PubMed ID: 4936247
[No Abstract] [Full Text] [Related]
15. Immunotherapy of guinea pig cancer with BCG.
Zbar B
Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
[No Abstract] [Full Text] [Related]
16. Effects of methanol extraction residue and therapeutic irradiation against established isografts and simulated local recurrence of mammary carcinomas.
Yron I; Cohen D; Robinson E; Haber M; Weiss DW
Cancer Res; 1975 Jul; 35(7):1779-90. PubMed ID: 1093676
[TBL] [Abstract][Full Text] [Related]
17. Immunological intervention in neoplasia.
Weiss DW
Johns Hopkins Med J Suppl; 1974; 3():131-56. PubMed ID: 4371312
[No Abstract] [Full Text] [Related]
18. Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype.
Hoft DF; Brown RM; Roodman ST
J Immunol; 1998 Jul; 161(2):1045-54. PubMed ID: 9670986
[TBL] [Abstract][Full Text] [Related]
19. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.
Robinson E; Bartal A; Cohen Y; Haasz R
Br J Cancer; 1975 Jul; 32(1):1-4. PubMed ID: 1100088
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
Yron I; Weiss DW; Robinson E; Cohen D; Adelberg MG; Mekori T; Haber M
Natl Cancer Inst Monogr; 1973 Dec; 39():33-55. PubMed ID: 4362523
[No Abstract] [Full Text] [Related]
[Next] [New Search]
